World Asthma Day 2026: New Anti-Inflammatory Drugs and More for Asthma Control

Key Takeaways

• Breztri Aerosphere approved as first single‑inhaler triple therapy for asthma
• Kinaset raised $103 M to develop inhaled pan‑JAK inhibitor frevecitinib
• AeroDel’s foldable PMDI enhancer aims to cut inhaler errors in India
• Access to anti‑inflammatory inhalers remains limited in low‑income regions
• GINA stresses affordable controller inhalers as urgent global priority

Pulse Analysis

Asthma continues to affect over 260 million people globally, accounting for more than 450,000 deaths each year. World Asthma Day 2026 reinforced the GINA call for universal access to anti‑inflammatory inhalers, emphasizing that cost and availability remain major barriers, especially in low‑ and middle‑income countries. While rescue bronchodilators relieve acute bronchoconstriction, only controller inhalers that target airway inflammation can prevent exacerbations and improve long‑term lung function.

The therapeutic landscape is evolving rapidly. AstraZeneca’s Breztri Aerosphere received FDA approval as the first single‑inhaler triple therapy, merging budesonide, glycopyrrolate and formoterol to simplify regimens and enhance adherence. Sanofi’s experimental biologic lunsekimig, which blocks TSLP and IL‑13, met Phase IIb endpoints, hinting at a new class of cytokine‑targeted asthma treatments. Kinaset Therapeutics, buoyed by a $103 million Series B round, is pushing frevecitinib—a pan‑JAK inhibitor delivered via dry‑powder inhalation—through Phase II trials, aiming to address patients who remain uncontrolled on existing inhaled therapies.

Device innovation is equally critical. AeroDel reported that up to 94 % of inhaler users commit at least one critical error, compromising drug delivery. Its partnership with Zydus Lifesciences to launch the Aerolife Mini—a foldable, always‑attached enhancer for pressurized metered‑dose inhalers—targets the Indian market, where improper technique is a pervasive issue. By reducing handling errors and improving portability, such technologies can boost the effective dose reaching the lungs, translating into better disease control and opening sizable market opportunities for manufacturers that prioritize user‑centric design.